Rezatapopt is under clinical development by PMV Pharmaceuticals and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II drugs for Endometrial Cancer have a 22% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Rezatapopt’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Rezatapopt overview
Rezatapopt (PC-14586) is under development for the treatment of advanced multiple tumor types including ovarian, breast, prostate, small-cell lung, and endometrial cancer. The drug candidate acts by targeting Y220C mutated p53. It is administered through oral route.
PMV Pharmaceuticals overview
PMV Pharmaceuticals (PMV) is a precision oncology company that discovers and develops small molecule drugs for the treatment of cancer. The company’s lead product candidate, PC14586 is a selective p53 reactivator designed for the treatment of patients with metastatic solid tumors that have a p53 Y220C mutation. It is also investigating a tumor-agnostic drug targeting the p53 R273H mutation. PMV carries out clinical trials, research, and development to provide unique therapies for any patient whose tumor harbors these gene mutations. PMV is headquartered in Cranbury, New Jersey, the US.
For a complete picture of Rezatapopt’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.